Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation
Veeva Systems (NYSE:VEEV) has announced a strategic collaboration with Amgen to enhance clinical trial innovation. Amgen will implement the Veeva Clinical Platform to optimize their clinical trial processes and accelerate drug development for serious diseases.
The collaboration includes implementation and change management support from Veeva Business Consulting. Amgen's CIO Scott Skellenger highlighted that this partnership aims to unlock new capabilities for end-to-end trial operations, while Veeva Development Cloud President Jim Reilly emphasized the platform's role in speeding up drug delivery through standardized and connected processes.
Veeva Systems (NYSE:VEEV) ha annunciato una collaborazione strategica con Amgen per potenziare l'innovazione nelle sperimentazioni cliniche. Amgen adotterà la Veeva Clinical Platform per ottimizzare i processi dei trial clinici e accelerare lo sviluppo di farmaci per malattie gravi.
La collaborazione prevede supporto all'implementazione e alla gestione del cambiamento da parte di Veeva Business Consulting. Scott Skellenger, CIO di Amgen, ha sottolineato che la partnership mira a sbloccare nuove capacità per operazioni di trial end-to-end, mentre Jim Reilly, Presidente di Veeva Development Cloud, ha evidenziato il ruolo della piattaforma nell'accelerare la consegna dei farmaci tramite processi standardizzati e connessi.
Veeva Systems (NYSE:VEEV) ha anunciado una colaboración estratégica con Amgen para impulsar la innovación en ensayos clínicos. Amgen implementará la Veeva Clinical Platform para optimizar sus procesos de ensayos clínicos y acelerar el desarrollo de medicamentos para enfermedades graves.
La colaboración incluye apoyo en implementación y gestión del cambio por parte de Veeva Business Consulting. Scott Skellenger, CIO de Amgen, destacó que la alianza pretende desbloquear nuevas capacidades para operaciones de ensayos de extremo a extremo, mientras que Jim Reilly, presidente de Veeva Development Cloud, subrayó el papel de la plataforma en acelerar la entrega de medicamentos mediante procesos estandarizados y conectados.
Veeva Systems (NYSE:VEEV)는 임상시험 혁신 강화를 위해 Amgen과 전략적 협력을 발표했습니다. Amgen은 임상시험 프로세스를 최적화하고 중증 질환 치료제 개발을 가속화하기 위해 Veeva Clinical Platform을 도입할 예정입니다.
이번 협력에는 Veeva Business Consulting의 도입 및 변화관리 지원이 포함됩니다. Amgen의 CIO 스콧 스켈렌저는 이 파트너십이 엔드투엔드(End-to-End) 시험 운영의 새로운 역량을 열어줄 것이라고 강조했으며, Veeva Development Cloud의 사장 짐 릴리는 표준화되고 연결된 프로세스를 통해 의약품 제공을 가속화하는 플랫폼의 역할을 강조했습니다.
Veeva Systems (NYSE:VEEV) a annoncé une collaboration stratégique avec Amgen pour renforcer l'innovation dans les essais cliniques. Amgen mettra en œuvre la Veeva Clinical Platform afin d'optimiser ses processus d'essais cliniques et d'accélérer le développement de médicaments pour les maladies graves.
La collaboration comprend un soutien à la mise en œuvre et à la gestion du changement de la part de Veeva Business Consulting. Scott Skellenger, CIO d'Amgen, a souligné que ce partenariat vise à libérer de nouvelles capacités pour les opérations d'essais de bout en bout, tandis que Jim Reilly, président de Veeva Development Cloud, a insisté sur le rôle de la plateforme pour accélérer la mise sur le marché des médicaments grâce à des processus standardisés et connectés.
Veeva Systems (NYSE:VEEV) hat eine strategische Zusammenarbeit mit Amgen angekündigt, um Innovationen in klinischen Studien voranzutreiben. Amgen wird die Veeva Clinical Platform einführen, um seine Prozesse in klinischen Studien zu optimieren und die Entwicklung von Arzneimitteln für schwere Erkrankungen zu beschleunigen.
Die Zusammenarbeit umfasst Implementierungs- und Change-Management-Unterstützung durch Veeva Business Consulting. Scott Skellenger, CIO von Amgen, betonte, dass die Partnerschaft neue Fähigkeiten für End-to-End-Studienoperationen freisetzen soll, während Jim Reilly, Präsident von Veeva Development Cloud, die Rolle der Plattform bei der Beschleunigung der Medikamentenzulieferung durch standardisierte und vernetzte Prozesse hervorhob.
- Partnership with major biotech company Amgen strengthens Veeva's market position
- Expansion of Veeva Clinical Platform adoption in the biotechnology sector
- Additional consulting services revenue through implementation support
- None.
"In collaboration with Veeva, we're leveraging advanced technology to unlock new capabilities for our end-to-end trial operations which are expected to further strengthen our ability to bring innovative treatments to patients with speed and scale," said Scott Skellenger, senior vice president and chief information officer at Amgen.
"We're excited to help Amgen further advance clinical development. Veeva Clinical Platform will provide the backbone for standard and connected processes that can speed the delivery of life-saving drugs to patients in need," said Jim Reilly, president of Veeva Development Cloud.
As part of the collaboration, Veeva Business Consulting will support Amgen through implementation and change management.
About Veeva Clinical Platform
Veeva Clinical Platform is a complete and connected platform across clinical operations and data applications. This end-to-end platform includes CTMS, EDC, clinical workbench (CDB), RTSM, eCOA, eTMF, Site Connect, Study Training, and more. Connected products streamline clinical trials from study start-up to close and automate a connected data flow. To learn more about Veeva Clinical Platform, visit veeva.com/VeevaClinicalPlatform.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-announces-collaboration-with-global-biotech-to-further-accelerate-clinical-trial-innovation-302540554.html
SOURCE Veeva Systems
FAQ
What is the new collaboration between Veeva Systems (NYSE:VEEV) and Amgen?
How will the Veeva Clinical Platform benefit Amgen's operations?
What support services is Veeva providing to Amgen in this collaboration?
Who are the key executives involved in the Veeva-Amgen collaboration?
